Gelteq Ltd (GELS) relative valueRV
GELS's operating margin of -3317.7% ranks in the 17th percentile of 14 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-12-31 and 2026-03-31.
Kresmion ranks GELS against its industry peers from annual SEC filings and market-price snapshots.
Against 16 Drug Manufacturers - Specialty & Generic peers
| Metric | GELS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 166K AUD | n/a | n/a | n/a |
| Revenue YoY | n/a | n/a | n/a | 4 |
| Gross margin | 30.3% | 49.0% | 21st | 11 |
| Operating margin | -3317.7% | -83.1% | 17th | 14 |
| Net margin | -4011.9% | -22.9% | 17th | 14 |
| Return on equity | -42.0% | -62.0% | 58th | 12 |
| P / E | n/a | n/a | n/a | n/a |
| 1 year | n/a | n/a | n/a | n/a |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2024-12-31 and 2026-03-31. Prices as of 2026-11-06. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001213900-25-111090
Peer set, 16 companies
SNOA, APUS, YCBD, RDHL, UPC, PRFX, CVSI, CABR, SBFM, AKAN, BFRI, CBIH, BUDZ, CPMD, AYTU, TXMD
Left out: PLSH (period gap), CTTH (period gap), INM (period gap), TRUFF (no annual filing), CNTMF (no annual filing), CANN (period gap), OPTH (no annual filing), PCYN (period gap), CBDL (no annual filing).
What could not be compared
- 20 The filer did not report this line in the filing used.
- 17 The price series does not reach back to the start of this window.
- 17 The denominator is zero or negative, so the ratio has no meaning.
- 15 Reported in a different currency than the subject. A level in another currency is not comparable and is not converted here.
- 5 This filer reports an ordinary share count and trades as a depositary receipt at a ratio Kresmion does not store, so price times shares would be wrong.
- 5 This company's latest fiscal year ends more than 335 days from the subject's, so it is a different economic year.
- 4 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 4 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
- 1 Not meaningful: the prior year is zero, negative, or too small a base for a percentage to describe. Both figures are shown instead.
- 1 No prior fiscal year in the same currency about twelve months earlier.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, and the filing behind every cell. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "GELS relative value, Kresmion", data as of 2025-11-17, https://kresmion.com/tools/relative-value/GELS. Upstream data: SEC EDGAR XBRL company facts.
Link to this data (HTML):
<a href="https://kresmion.com/tools/relative-value/GELS">GELS relative value, Kresmion (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures